Connect your AI

Zymeworks ZYME Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation

Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation at other companies

Charles River LaboratoriesCRL

$8.3M+168%

BioCryst PharmaceuticalsBCRX

$56K+47.4%

Other financials

Income statement

Revenue$2.4M-91.1%

Operating income-$47.1M-84.0%

Net income-$44.2M-95.1%

EPS (diluted)-$0.59-96.7%

Balance sheet

Cash & equivalents$244.3M+221%

Total debt$17.0M-7.7%

Total equity$163.6M-49.7%

Total assets$478.2M+12.4%

Cash flow

Operating cash flow-$45.7M-1,242%

CapEx$216.0K+1,250%

Free cash flow-$45.9M-1,242%

Valuation

Market cap$1.76B+125%

Enterprise value$1.53B+112%

P/S21.6×+13.2×

Profitability

Operating margin-140.4%+7.3pp

Net margin-126.3%+5.0pp

FCF margin-94.8%+15.5pp

Returns & leverage

Return on equity-42%+29.2pp

Debt / equity0.1×0.0×

Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation.

The official record: Zymeworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's share-based payment arrangement, decrease for tax withholding obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Zymeworks's share-based payment arrangement, decrease for tax withholding obligation?: Zymeworks (ZYME) reported share-based payment arrangement, decrease for tax withholding obligation of $361K in Q1 2026.